Paper Details

  1. Home
  2. Paper Details

Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine.

Author: FregoRoberto, GuslandiMario, TestoniPier Alberto, VialeEdi

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the possible therapeutic benefit of transdermal nicotine versus oral mesalamine in 30 patients with left-sided ulcerative colitis unresponsive to treatment with a mesalamine 4 g enema at bedtime. Remission was observed in 12 of 15 patients receiving additional treatment with nicotine and in five of 15 patients receiving additional treatment with oral mesalamine (P=0.027). The addition of transdermal nicotine to treatment with mesalamine enemas is significantly superior to combined therapy with oral and rectal mesalamine in patients with distal ulcerative colitis refractory to rectal mesalamine alone.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Distal ulcerative colitis usually responds to treatment with rectal mesalamine, but the management of refractory cases is poorly defined. AIM: To evaluate the possible therapeutic benefit of transdermal nicotine versus oral mesalamine. PATIENTS AND METHODS: Thirty patients with left-si...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1155/2002/307218

データ提供：米国国立医学図書館（NLM）

Refractory Ulcerative Colitis: A Case for Transdermal Nicotine

Ulcerative colitis, a chronic inflammatory bowel disease, can be challenging to treat, especially when conventional therapies fail to produce desired results. This study examines the effectiveness of transdermal nicotine in treating distal ulcerative colitis, a form of the disease affecting the lower part of the colon, that has not responded to standard treatment with rectal mesalamine. The researchers sought to compare the effectiveness of transdermal nicotine with oral mesalamine in patients experiencing this type of refractory colitis.

Transdermal Nicotine: A Potential Breakthrough for Refractory Colitis

The study found that patients treated with transdermal nicotine, in addition to rectal mesalamine, experienced a significantly higher rate of clinical remission compared to those treated with oral mesalamine. This suggests that transdermal nicotine could be a valuable therapeutic option for patients with distal ulcerative colitis that has not responded to traditional treatments. The researchers emphasize the need for further investigation into the mechanisms by which nicotine exerts its effects in ulcerative colitis.

Finding Relief in the Desert of Inflammatory Bowel Disease

This research offers a glimmer of hope for individuals struggling with refractory ulcerative colitis. While transdermal nicotine may not be a suitable option for everyone, it provides a potential alternative for those who have not responded to traditional therapies. It is crucial to consult with your doctor to determine if this treatment is appropriate for you. Further research is needed to fully understand the potential benefits and risks of this approach.

Dr. Camel's Conclusion

The desert of inflammatory bowel disease can be a harsh and unforgiving landscape, but this research provides a potential oasis of relief. Transdermal nicotine presents a new avenue for those seeking a treatment solution, offering a glimpse of hope for a more comfortable and manageable future.

Date :
  1. Date Completed 2002-08-14
  2. Date Revised 2019-06-07
Further Info :

Pubmed ID

12045777

DOI: Digital Object Identifier

10.1155/2002/307218

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.